REYKJAVIK, ICELAND (June 15, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar...

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding a transaction of managers and closely associated persons, announcing the allocation...

REYKJAVIK, Iceland, June 8, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

REYKJAVIK, Iceland, June 4, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg.  All of the draft resolutions...

REYKJAVIK, ICELAND (June 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...

REYKJAVIK, ICELAND (June 1, 2026) — Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making agreement. According to the agreement, Islandsbanki places bids and...

Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, ICELAND – May 11, 2026 – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the...

Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights  A supplemental long‑form earnings release providing additional operational details and business update for Q1...

REYKJAVIK, ICELAND (April 30, 2026) — Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...